News & Trends - Biotechnology
Brisbane-based Microba partners with UNSW Sydney’s Microbiome Research Centre to deliver world-class analysis
Australia’s gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre (MRC) at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.
The collaboration between Microba and the MRC combines world-class microbiome analysis with leading clinicians and scientists, sharing a vision to not only discover new links with disease states, but with the ultimate goal of developing new diagnostics and therapies to help patients.
MRC held its official opening 12 August and will investigate how disturbance in the microbiome occurs and how it causes disease – a critical step in preventing it.
Microba co-founder and microbiome research pioneer, Professor Phil Hugenholtz welcomed the partnership, explaining that this opportunity would enable some of Australia’s best researchers to access the best analytical tools available.
“We hope that by furthering our knowledge of the gut microbiome, we will be able to improve the health and wellbeing of individuals. This collaboration allows all parties involved to contribute to this vision,” he said.
“With at least half of the population complaining of a digestive issue each year, high-powered research is essential to provide diagnostics and therapeutics into the future.”
The MRC is directed by UNSW Medicine Professor Emad El-Omar, a well recognised clinical gastroenterologist specialist with 20 years of gut microbiome research experience. Professor El-Omar is also the Editor in Chief of the highly reputable journal, Gut.
“We are delighted to collaborate with Microba, a company underpinned by outstanding scientists at the cutting edge of research in the microbiome field,” he said.
“Our complementary strengths will deliver real benefits to patients the world over.
“The microbiome is an exciting new frontier in medicine and together we will harness its power to treat and prevent disease.”
You may also like Australian Biotech 2030 Vision to emerge from AusBiotech CEO Policy Forum
News & Trends - MedTech & Diagnostics
AI-assisted colonoscopy boosts polyp and adenoma detection
MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]
MoreNews & Trends - Pharmaceuticals
‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO
Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]
MoreNews & Trends - Pharmaceuticals
Government’s silence on Senate report leaves cancer patients in limbo
Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]
More